Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges

Traditionally, Parkinson’s disease (PD) has been considered a single neurotransmitter (dopaminergic) disease. However, research over the past 20 years has shed light on the involvement of multiple neurotransmission systems, in particular, the cholinergic system. Research has mainly focused on the ro...

ver descrição completa

Detalhes bibliográficos
Autores: Martín Rodríguez, Juan Francisco, Mir Rivera, Pablo
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2020
País:España
Recursos:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/172571
Acesso em linha:https://hdl.handle.net/11441/172571
https://doi.org/10.1016/j.neulet.2018.06.048
Access Level:acceso abierto
Palavra-chave:short afferent inhibition
Parkinson’s disease
dopaminergic therapy
cognitive impairment
meta-analysis
id ES_3e4765b7c18aa96bc5cab5cf445014da
oai_identifier_str oai:idus.us.es:11441/172571
network_acronym_str ES
network_name_str España
repository_id_str
spelling Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challengesMartín Rodríguez, Juan FranciscoMir Rivera, Pabloshort afferent inhibitionParkinson’s diseasedopaminergic therapycognitive impairmentmeta-analysisTraditionally, Parkinson’s disease (PD) has been considered a single neurotransmitter (dopaminergic) disease. However, research over the past 20 years has shed light on the involvement of multiple neurotransmission systems, in particular, the cholinergic system. Research has mainly focused on the role of this system in the pathophysiology of PD and its implications in the development of motor and non-motor disorders. Short-latency sensory afferent inhibition (SAI), investigates sensori-motor integration, and has emerged as a putative neurophysiological marker of cholinergic function in the human brain. In this quantitative review, a moderate-to-severe reduction in SAI was observed in PD patients. Furthermore, through moderator analysis, the impairment of SAI was shown to be associated with disease duration and therapeutic state. Patients under dopaminergic agents (“on” state) displayed worse SAI than those after dopaminergic agent withdrawal (“off”). We further assess the potential value of SAI as a marker of cognitive impairment in PD, and its association with four specific cognitive domains. This analysis revealed that patients with cognitive impairment displayed significantly lower levels of SAI than those without cognitive impairment. To conclude, a set of challenges to be addressed before SAI can be validated as a useful clinical tool in PD are presented.ElsevierMedicinaPsicología ExperimentalJunta de AndalucíaFundación Alicia KoplowitzFundación Mutua MadrileñaFundación Progreso y SaludInstituto de Salud Carlos IIIEuropean Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)Sociedad Andaluza de Neurología2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/172571https://doi.org/10.1016/j.neulet.2018.06.048reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésNeuroscience Letters, 719, 133679.CVI-02526CTS-7685PI-0437-2012PI-0471/2013FPS 2014 PI-0055-2014PI14/01823PI16/01575https://www.sciencedirect.com/science/article/abs/pii/S0304394018304518?via%3Dihubinfo:eu-repo/semantics/openAccessoai:idus.us.es:11441/1725712026-06-17T12:51:07Z
dc.title.none.fl_str_mv Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
title Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
spellingShingle Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
Martín Rodríguez, Juan Francisco
short afferent inhibition
Parkinson’s disease
dopaminergic therapy
cognitive impairment
meta-analysis
title_short Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
title_full Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
title_fullStr Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
title_full_unstemmed Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
title_sort Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges
dc.creator.none.fl_str_mv Martín Rodríguez, Juan Francisco
Mir Rivera, Pablo
author Martín Rodríguez, Juan Francisco
author_facet Martín Rodríguez, Juan Francisco
Mir Rivera, Pablo
author_role author
author2 Mir Rivera, Pablo
author2_role author
dc.contributor.none.fl_str_mv Medicina
Psicología Experimental
Junta de Andalucía
Fundación Alicia Koplowitz
Fundación Mutua Madrileña
Fundación Progreso y Salud
Instituto de Salud Carlos III
European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)
Sociedad Andaluza de Neurología
dc.subject.none.fl_str_mv short afferent inhibition
Parkinson’s disease
dopaminergic therapy
cognitive impairment
meta-analysis
topic short afferent inhibition
Parkinson’s disease
dopaminergic therapy
cognitive impairment
meta-analysis
description Traditionally, Parkinson’s disease (PD) has been considered a single neurotransmitter (dopaminergic) disease. However, research over the past 20 years has shed light on the involvement of multiple neurotransmission systems, in particular, the cholinergic system. Research has mainly focused on the role of this system in the pathophysiology of PD and its implications in the development of motor and non-motor disorders. Short-latency sensory afferent inhibition (SAI), investigates sensori-motor integration, and has emerged as a putative neurophysiological marker of cholinergic function in the human brain. In this quantitative review, a moderate-to-severe reduction in SAI was observed in PD patients. Furthermore, through moderator analysis, the impairment of SAI was shown to be associated with disease duration and therapeutic state. Patients under dopaminergic agents (“on” state) displayed worse SAI than those after dopaminergic agent withdrawal (“off”). We further assess the potential value of SAI as a marker of cognitive impairment in PD, and its association with four specific cognitive domains. This analysis revealed that patients with cognitive impairment displayed significantly lower levels of SAI than those without cognitive impairment. To conclude, a set of challenges to be addressed before SAI can be validated as a useful clinical tool in PD are presented.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/172571
https://doi.org/10.1016/j.neulet.2018.06.048
url https://hdl.handle.net/11441/172571
https://doi.org/10.1016/j.neulet.2018.06.048
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Neuroscience Letters, 719, 133679.
CVI-02526
CTS-7685
PI-0437-2012
PI-0471/2013
FPS 2014 PI-0055-2014
PI14/01823
PI16/01575
https://www.sciencedirect.com/science/article/abs/pii/S0304394018304518?via%3Dihub
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406522514079744
score 15,811543

Registos relacionados